• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    12/21/23 8:07:41 AM ET
    $ACON
    $ARGX
    $BLUE
    $ERNA
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Aclarion (NASDAQ:ACON) shares rose 70.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $4.6 million.
    • TRACON Pharma (NASDAQ:TCON) shares moved upwards by 47.92% to $0.28. The company's market cap stands at $8.6 million.
    • Eterna Therapeutics (NASDAQ:ERNA) stock moved upwards by 22.8% to $1.87. The market value of their outstanding shares is at $10.0 million.
    • Passage Bio (NASDAQ:PASG) shares increased by 21.23% to $0.92. The market value of their outstanding shares is at $50.4 million.
    • NuCana (NASDAQ:NCNA) stock moved upwards by 16.6% to $0.4. The company's market cap stands at $21.2 million.
    • Regional Health Props (AMEX:RHE) stock rose 16.27% to $2.5. The market value of their outstanding shares is at $4.7 million.

    Losers

    • bluebird bio (NASDAQ:BLUE) shares decreased by 51.9% to $1.17 during Thursday's pre-market session. The company's market cap stands at $128.0 million.
    • Jin Medical International (NASDAQ:ZJYL) stock declined by 30.63% to $79.0. The company's market cap stands at $612.2 million.
    • argenx (NASDAQ:ARGX) stock decreased by 24.68% to $340.9. The market value of their outstanding shares is at $20.1 billion.
    • Xilio Therapeutics (NASDAQ:XLO) stock decreased by 17.89% to $0.49. The company's market cap stands at $13.5 million.
    • Ontrak (NASDAQ:OTRK) stock declined by 12.76% to $0.39. The company's market cap stands at $10.7 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares decreased by 12.52% to $0.33. The company's market cap stands at $2.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ARGX
    $BLUE
    $ERNA

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    argenx SE
    $ARGX
    12/18/2025$858.00Outperform → Neutral
    Robert W. Baird
    argenx SE
    $ARGX
    11/24/2025Outperform → Peer Perform
    Wolfe Research
    argenx SE
    $ARGX
    9/15/2025$918.00Buy
    Truist
    argenx SE
    $ARGX
    9/11/2025Buy → Hold
    Deutsche Bank
    argenx SE
    $ARGX
    8/25/2025$850.00Outperform
    RBC Capital Mkts
    Xilio Therapeutics Inc.
    $XLO
    8/6/2025$2.00Outperform
    Leerink Partners
    argenx SE
    $ARGX
    7/8/2025Hold → Buy
    Deutsche Bank
    More analyst ratings

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Gilead Sciences, Inc.

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    2/17/26 5:31:38 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Chou William converted options into 10,000 shares and sold $75,159 worth of shares (4,076 units at $18.44), increasing direct ownership by 987% to 6,524 units (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    1/12/26 4:03:52 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

    Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-f

    3/6/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

    Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Advancing differentiated preclinical program for Huntington's with clinical candidate selection expected in 2H 2026 Cash runway through 1Q 2027 PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results

    3/3/26 7:00:00 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET. A live webcast can be accessed under "Events & Presentations" in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation. About Xilio Therapeutics Xilio Therapeutics is a clinica

    3/2/26 8:00:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded argenx from Outperform to Neutral and set a new price target of $858.00

    12/18/25 8:54:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx downgraded by Wolfe Research

    Wolfe Research downgraded argenx from Outperform to Peer Perform

    11/24/25 8:14:37 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    SEC Filings

    View All

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    3/6/26 6:15:09 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Passage Bio Inc.

    S-8 - Passage BIO, Inc. (0001787297) (Filer)

    3/4/26 4:05:38 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Passage Bio Inc.

    10-K - Passage BIO, Inc. (0001787297) (Filer)

    3/3/26 7:15:58 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Large owner Lynx1 Capital Management Lp bought $2,261 worth of shares (325 units at $6.96) and bought $221,474 worth of shares (31,683 units at $6.99) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    9/15/25 8:05:45 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    argenx Announces Leadership Transition Marking Next Evolution of Growth

    Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director and Tim Van Hauwermeiren, current Chief Executive Officer, will transition to non-Executive Director and Chairman of the Board of Directors. Tim will succeed Peter Verhaeghe, w

    1/5/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

    CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

    12/2/25 8:50:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Financials

    Live finance-specific insights

    View All

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

    February 19, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium           32 800 50

    2/19/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ACON
    $ARGX
    $BLUE
    $ERNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care